DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Nd-630, 1434635-54-7, Gs-acc, Ndi-010976, Gs-0976, Firsocostat [usan]

Molecular Formula

C₂₈H₃₁N₃O₈S

Molecular Weight

569.6 g/mol

InChI Key

ZZWWXIBKLBMSCS-FQEVSTJZSA-N

FDA UNII

XE10NJQ95M

Firsocostat is under investigation in clinical trial NCT02781584 (Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)).

1 2D Structure

Firsocostat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid

2.1.2 InChI

InChI=1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)/t20-/m0/s1

2.1.3 InChI Key

ZZWWXIBKLBMSCS-FQEVSTJZSA-N

2.1.4 Canonical SMILES

CC1=C(SC2=C1C(=O)N(C(=O)N2CC(C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5

2.1.5 Isomeric SMILES

CC1=C(SC2=C1C(=O)N(C(=O)N2C[C@@H](C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5

2.2 Other Identifiers

2.2.1 UNII

XE10NJQ95M

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(1-((2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl)-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno(2,3-d)pyrimidin-3-yl)-2-methylpropanoic Acid

2. Gs-0976

2.3.2 Depositor-Supplied Synonyms

1. Nd-630

2. 1434635-54-7

3. Gs-acc

4. Ndi-010976

5. Gs-0976

6. Firsocostat [usan]

7. Xe10njq95m

8. 2-[1-[(2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic Acid

9. (r)-2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2h)-yl)-2-methylpropanoic Acid

10. 2-(1-((2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl)-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno(2,3-d)pyrimidin-3-yl)-2-methylpropanoic Acid

11. Firsocostat [inn]

12. Firsocostat (usan/inn)

13. Unii-xe10njq95m

14. Firsocostat (gs-0976)

15. Firsocostat [who-dd]

16. Schembl14945041

17. Gtpl10645

18. Amy16826

19. Ex-a2586

20. Firsocostat(nd-630,gs-0976)

21. Nd 630;nd630

22. S8893

23. Who 10738

24. Akos037648731

25. Zinc207531097

26. Cs-6509

27. Ac-31460

28. Bs-15388

29. Hy-16901

30. Nd-630; Ndi-010976; Firsocostat

31. D11640

32. 1,4-dihydro-1-((2r)-2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-.alpha.,.alpha.,5-trimethyl-6-(2-oxazolyl)-2,4-dioxothieno(2,3-d)pyrimidine-3(2h)-acetic Acid

33. 1,4-dihydro-1-((2r)-2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-alpha,alpha,5-trimethyl-6-(2-oxazolyl)-2,4-dioxothieno(2,3-d)pyrimidine-3(2h)-acetic Acid

34. 2-[1-[(r)-beta-[(tetrahydro-2h-pyran-4-yl)oxy]-2-methoxyphenethyl]-2,4-dioxo-5-methyl-6-(oxazole-2-yl)-1,2-dihydrothieno[2,3-d]pyrimidine-3(4h)-yl]-2-methylpropanoic Acid

35. Thieno(2,3-d)pyrimidine-3(2h)-acetic Acid, 1,4-dihydro-1-((2r)-2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-.alpha.,.alpha.,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-

2.4 Create Date

2013-06-11

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₃₁N₃O₈S
Molecular Weight	569.6 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	9
Exact Mass	569.18318613 g/mol
Monoisotopic Mass	569.18318613 g/mol
Topological Polar Surface Area	160 Å²
Heavy Atom Count	40
Formal Charge	0
Complexity	947
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

Drugs in Development